# AeroRx Therapeutics

> AeroRx Therapeutics is a San Diego clinical-stage biopharma building nebulized combination drugs for chronic obstructive pulmonary disease. Its lead candidate, AERO-007, is the first dual bronchodilator (LABA/LAMA) designed to be delivered through a standard jet nebulizer instead of a hand-held inhaler - aimed at the older, sicker patients who struggle to work a puffer. Positive Phase 2a data landed in July 2025, and the company closed a $21 million Series A that October to push toward late-stage trials.

- **Founded:** 2023
- **Headquarters:** San Diego, California, United States
- **Founders:** Ahmet Tutuncu (CEO & Co-founder)
- **Team size:** ~3 employees
- **Products:** AERO-007, AERO-111
- **Notable:** Announced positive topline Phase 2a data for AERO-007 in July 2025, showing sustained 24-hour bronchodilation at both doses, Closed a $21 million Series A in October 2025 led by Avalon BioVentures, Positioned AERO-007 as the first nebulized LABA/LAMA combination in development for COPD

## Products & services

- **AERO-007** — A fixed-dose LABA/LAMA dual bronchodilator (indacaterol + glycopyrrolate) formulated for delivery through a standard jet nebulizer - positioned as the first nebulized LABA/LAMA combination for first-line COPD maintenance. Phase 2a data showed statistically significant, sustained 24-hour bronchodilation at both dose levels.
- **AERO-111** — A nebulized LABA/LAMA/ICS triple-combination therapy adding an inhaled corticosteroid for COPD patients needing anti-inflammatory treatment. In IND-enabling development.

## Achievements

- Announced positive topline Phase 2a data for AERO-007 in July 2025, showing sustained 24-hour bronchodilation at both doses
- Closed a $21 million Series A in October 2025 led by Avalon BioVentures
- Positioned AERO-007 as the first nebulized LABA/LAMA combination in development for COPD
- Founder's prior track record includes three drug approvals, including Lonhala Magnair for COPD

## Latest updates

- **2025-10** — Closed $21 million Series A led by Avalon BioVentures to advance AERO-007 into late-stage clinical development.
- **2025-07** — Announced positive topline Phase 2a data for AERO-007, showing statistically significant 24-hour bronchodilation.

## Links

- Website: https://aerorxtx.com
- LinkedIn: http://www.linkedin.com/company/aerorx-therapeutics

---

Profile page: https://yespress.io/aerorx-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-08-19